Circular RNAs (circRNAs) are significantly dysregulated in various cancer types. However, the roles and mechanisms of circRNAs in cancer remain largely unknown. In this study, we demonstrated that a novel circRNA (circITGA7) and its linear host gene ITGA7 are both significantly downregulated in colorectal cancer (CRC) tissues and cell lines. These decreased expression levels correlated with CRC progression. Functional assays demonstrated that ectopic circITGA7 expression suppressed the growth and metastasis of CRC cells in vitro and in vivo. Knockdown of circITGA7 or ITGA7 promoted the proliferation and migration of CRC cells in vitro, and enhanced CRC growth in vivo. Mechanistically, by using RNA-sequencing and KEGG enrichment analysis, we found that circITGA7 is a negative regulator of the Ras signalling pathway, and that ITGA7 is associated with cytokine-related signalling pathways. In addition, circITGA7 binds to miR-370-3p to antagonise its suppression of neurofibromin 1, which is a well-known negative regulator of the Ras pathway. Finally, circITGA7 upregulates the transcription of ITGA7 by suppressing RREB1 via the Ras pathway. In conclusion, our findings indicate a suppressor role of circITGA7 and ITGA7 in CRC, and reveal that circITGA7 inhibits the proliferation and metastasis of CRC cells by suppressing the Ras signalling pathway and promoting the transcription of ITGA7, suggesting that circITGA7 is a potential target for CRC treatment.
Introduction
Colorectal cancer (CRC) is a common digestive tract malignancy with high morbidity and mortality. Although the diagnosis and treatment of CRC have improved, it still contributes significantly to cancer-related death [1] . Therefore, unravelling the mechanisms underlying CRC carcinogenesis and metastasis may provide novel insights into CRC management.
Circular RNAs (circRNAs) are characterised by single-stranded closed-loop structures, in which 3 ′ and 5
′ termini are joined together [2] . Following the advent of high-throughput sequencing and computational approaches, thousands of circRNAs have been identified. The majority of circRNAs are exonic circRNAs, which are derived from exonic regions of known protein-coding genes by back-splicing [3] . CircRNAs have the potential to be biomarkers, owing to their stable and highly conserved features [4] . Moreover, certain circRNAs are abundant and stable in plasma and exosomes [5, 6] , which provides a more convenient means of detection. To date, several circRNAs have been proposed as biomarkers for the diagnosis or prognosis of gastric, lung and colorectal cancers [7] . The downregulation of hsa_circ_0000190 and hsa_circ_002059 in the plasma samples of gastric cancer patients can be diagnostic [8, 9] .
In recent years, an increasing number of studies have identified certain dysregulated circRNAs in cancer that play crucial roles in carcinogenesis and malignant behaviour generally, by sponging microRNA (miRNA). For example, the well-known ciRS7 abrogates the tumour suppressive effect of miR-7 to promote theCircITGA7 inhibits CRC growth and metastasis 167 carcinoma proliferation and invasion by acting as an miR-9 sponge to regulate p21 expression [12] . Furthermore, circRNA_100290 upregulates cyclin-dependent kinase 6 expression through the binding of miR-29 family members to promote proliferation in oral cancer [13] . Other mechanisms identified include circFoxo3 binding to cyclin-dependent kinase 2 and p21 to repress cell cycle progression [14] , and circAmotl1 binding to c-Myc to enhance its stability and increase its nuclear accumulation to promote tumourigenesis [15] . A few circRNAs (e.g. circFBXW7) are even able to encode functional proteins [16] . However, the functions and mechanisms of the majority of circRNAs in cancer remain largely unexplored.
CircITGA7 (circBase ID: hsa_circ_0026782 [17] ) is a novel circRNA derived from exon 4 of the integrin subunit alpha 7 (ITGA7) gene by back-splicing, whereas its corresponding linear ITGA7 is formed by canonical linear splicing. It has been reported that downregulation of ITGA7 in malignant pleural mesothelioma increases cell migration potential [18] . In prostate cancer and leiomyosarcoma, forced expression of ITGA7 suppresses tumour growth and metastasis in vitro and in vivo [19] . Furthermore, elevated ITGA7 expression reduces cell motility, metastasis and tumour growth in melanoma [20] . These studies suggest that ITGA7 plays an inhibitory role in cancer. However, circITGA7 and ITGA7 expression and function in CRC have not been reported.
In this study, we determined that both circITGA7 and ITGA7 are downregulated in CRC clinical samples and cell lines. Functional assays revealed their role in the inhibition of CRC growth and metastasis in vitro and in vivo. In addition, circITGA7 inhibited CRC growth and metastasis through modulation of the Ras pathway and at least in part by upregulating ITGA7 transcription.
Materials and methods

Ethics statement
All animal experiments were carried out strictly according to the National Institutes of Health Guidelines for Laboratory Animal Care [21] and Guidelines for the Welfare and Use of Animals in Cancer Research [22] . The protocol and the use of clinical materials for research purposes were approved by the Ethics Committee of Southern Medical University. Consent forms were signed by all patients according to the ethical protocols of Nanfang Hospital, Southern Medical University.
Tissue samples
CRC samples and paired adjacent non-cancerous colorectal tissues were collected from the surgically removed colorectal carcinoma specimens at Nanfang Hospital, Southern Medical University (Guangzhou, PR China). Details are provided in supplementary material, Supplementary materials and methods.
Cell culture
The seven CRC cell lines (SW480, RKO, Caco-2, SW620, LoVo, HCT116, and DLD1) and the normal human colonic epithelial cell line FHC were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and authenticated according to the ATCC recommendations. Details are provided in supplementary material, Supplementary materials and methods.
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
RT-qPCR was performed with SybrGreen qPCR Mastermix (DBI Bioscience, Ludwigshafen, Germany) and the All-in-One miRNA qRT-PCR Detection System (GeneCopoeia, Rockville, MD, USA), according to the manufacturer's instructions. The relative expression levels of genes were calculated with the ΔΔCT method [23] . Primer sequences are listed in supplementary material, Table S1 . Details are provided in supplementary material, Supplementary materials and methods.
RNase R and actinomycin D treatment
Details are provided in supplementary material, Supplementary materials and methods.
Construction of cells stably overexpressing circITGA7
Overexpression of circITGA7 was achieved as in a previous study [24] . Liang et 
Fluorescence in situ hybridisation
Cy3-labelled DNA oligonucleotide probes crossing the splice junction against circITGA7 were designed and synthesised by RiboBio. The hybridisation reactions were performed with a fluorescence in situ hybridisation (FISH) kit (RiboBio), according to the manufacturer's protocol and a previous study [25] . Details are provided in supplementary material, Supplementary materials and methods. Filtering restrictions were as follows: total score, ≥140; normalised free energy, >1; and minimum free energy, <-25 kcal/mol. The prediction was performed by Geenseed Biotech (Guangzhou, PR China).
Separation of cytoplasmic and nuclear fractions
Details of other methods [RNA extraction, reverse transcription, DNA extraction, polymerase chain reaction (PCR), Sanger sequencing, MTT assay, colony formation assay, cell cycle analysis, cell wound healing assay, cell migration and invasion assays, xenograft growth and metastasis assays in vivo, western blotting, immunohistochemistry (IHC), luciferase reporter assay, and chromatin immunoprecipitation (ChIP)] are provided in our previous articles [26, 27] and in supplementary material, Supplementary materials and methods.
Statistical analysis
Statistical analyses were performed with SPSS20.0 software (IBM, Armonk, NY, USA) and GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA). Data are presented as mean ±standard deviation. The differences between groups were tested with a two-tailed Student's t-test, one-way ANOVA, or χ 2 test. Relationships between circITGA7 or ITGA7 expression and clinicopathological characteristics were determined with a two-tailed Student's t-test or one-way ANOVA. The receiver operating characteristic (ROC) curve was built with GraphPad Prism. The image data of western blots were analysed with a Gel-pro analyser (Media Cybernetics, Rockville, MD, USA). IHC images of orthotopic tumours were quantified with Image-pro Plus 6.0 (Media Cybernetics). Differences were considered to be significant at p < 0.05.
Results
CircITGA7 is generated from exon 4 of ITGA7 by back-splicing
In this study, we focused on circITGA7 because it was the most downregulated circRNA among the 203 downregulated and 57 upregulated circRNAs identified in CRC by the use of deep sequencing [28] . CircITGA7 is generated from exon 4 of ITGA7 by back-splicing (256 nucleotides). We designed specific divergent primers spanning the back-splice junction site of circITGA7 to detect circITGA7, and the specificities of the divergent primers were validated with melting curve analysis of the RT-qPCR-amplified product, which showed a single peak (supplementary material, Figure S3 ). In addition, convergent primers, which crossed exon 7 to exon 9 of ITGA7, were designed to detect linear ITGA7 ( Figure 1A ).
We performed a set of experiments to confirm that circITGA7 harbours a closed-loop structure that is not produced by trans-splicing or genomic rearrangements. First, we amplified circITGA7 and ITGA7 from cDNA and genomic DNA (gDNA) by using the divergent and convergent primers, respectively. The results showed that the back-splice junction sequences of circITGA7 existed only in the cDNA. In contrast, the convergent primers amplified ITGA7 from both cDNA and gDNA ( Figure 1B) . The back-splice junction sequences were validated by Sanger sequencing ( Figure 1C ). Furthermore, RNase R was used to validate the circular form of circITGA7, because RNase R can digest linear RNA but is incapable of cutting circRNAs [29] . As expected, circITGA7 was more resistant to RNase R digestion than linear ITGA7 and GAPDH transcripts ( Figure 1D,E) . Furthermore, the inhibition of new RNA synthesis by actinomycin D further provided evidence that circITGA7 was more stable than linear ITGA7 ( Figure 1F ). These data suggest that circITGA7 is a circRNA that is generated from exon 4 of ITGA7 by back-splicing.
CircITGA7 and ITGA7 are both downregulated in CRC, and their downregulation is correlated with CRC progression
The expression of circITGA7 and ITGA7 in CRC tissues and adjacent non-cancerous tissues was detected by RT-qPCR. The results showed that circITGA7 was significantly downregulated, by 91.38%, in 67 of 69 CRC tissues, and that ITGA7 was downregulated by 58% in (Figure 2A-D) . IHC was performed to detect ITGA7 protein expression in 60 paired paraffin-embedded CRC and adjacent non-cancerous tissues. ITGA7 showed weak to strong staining in 48 non-cancerous tissues, and was undetectable in 12 non-cancerous tissues. In contrast, ITGA7 staining was weak or moderate in 20 CRC tissues but negative in the other 40. The positive expression rate of ITGA7 in CRC tissues (33.33%) was significantly lower than in adjacent non-cancerous tissues (80%) ( Figure 2E ). Consistent with the IHC data, western blotting showed that ITGA7 expression was decreased in eight surgical CRC tissues as compared with the adjacent non-cancerous tissues ( Figure 2F ). In addition, the expression of circITGA7 and ITGA7 in seven CRC cell lines (i.e. SW480, RKO, Caco-2, SW620, LoVo, HCT116, and DLD1) was also lower than in the normal CRC cell line FHC. Moreover, the expression level was lower in SW620, a CRC cell line with high metastatic potential, than in SW480, a CRC cell line with low metastatic potential ( Figure 2G,H) .
of 48 CRC tissues
To further investigate the potential clinical significance of circITGA7 and ITGA7 in CRC, we constructed ROC curves, using the relative expression levels of circITGA7 and ITGA7 in CRC tissues and paired non-cancerous tissues to evaluate their diagnostic values. The area under the curve (AUC) of circITGA7 was 0.8791, with a sensitivity of 0.9275 and a specificity of 0.6667, which was much higher than that of ITGA7 (AUC of 0.7402) ( Figure 2I ). These data indicate circITGA7 has potential as a biomarker for CRC diagnosis. Furthermore, the relationships between circITGA7 or ITGA7 expression and the clinicopathological factors of CRC patients were analysed. As shown in supplementary material, Tables S3 and S4, circITGA7 expression levels were inversely correlated with tumour size, lymph metastasis, distant metastasis, and TNM stage. However, low expression of ITGA7 was associated only with distant metastasis. These results suggest that circITGA7 and ITGA7 are both downregulated in CRC, and that their downregulation is associated with CRC progression.
CircITGA7 and ITGA7 both inhibit CRC cell proliferation and metastasis
To investigate the role of circITGA7 and ITGA7 in CRC, we established cell lines stably overexpressing circITGA7 (supplementary material, Supplementary materials and methods and Figure S1 ). MTT and colony formation assays demonstrated that ectopic circITGA7 expression inhibited CRC cell proliferation ( Figure 3A,B) . Flow cytometry analysis showed that the cell cycle of these cells was stalled in the G 0 /G 1 phase (supplementary material, Figure S4 ), which suggests that overexpression of circITGA7 inhibited the G 1 /S phase transition in CRC cells. Furthermore, overexpression of circITGA7 decreased cell migration and invasion Figure 3C,D) . These data indicate that overexpression of circITGA7 inhibited CRC cell proliferation and migration in vitro.
Consistent with the findings in vitro, overexpression of circITGA7 inhibited subcutaneous xenograft growth in vivo (Figure 3E,F) . Using intrasplenic injection and orthotopic metastasis models, we evaluated the effect of circITGA7 on CRC metastasis. In the intrasplenic injection model, 83% (5/6) of control mice injected with SW620-NC (negative control) cells had metastatic nodules in the liver. However, only 33% (2/6) of the mice injected with SW620-circITGA7 cells had hepatic metastases. The number of liver metastases in mice in the circITGA7 overexpression group was also lower than that in the control group (Figure 3G-I) . Fewer mice in the orthotopic model had hepatic metastases, and the number of liver metastases was lower in the circITGA7 overexpression group than in the control group (supplementary material, Figure S5 ).
In contrast, knockdown of circITGA7 promoted CRC cell proliferation and migration, as demonstrated with the MTT and Transwell assays. Similar effects were observed following the knockdown of ITGA7. Furthermore, stable knockdown of circITGA7 or ITGA7 enhanced the growth of xenografts (supplementary material, Figure S6 ). These results indicate that circITGA7 and ITGA7 both suppressed CRC cell proliferation and migration.
CircITGA7 is a negative regulator of the Ras signalling pathway, whereas ITGA7 is involved in cytokine-related pathways
To explore the mechanisms underlying the effects of circITGA7 and ITGA7 on CRC cell proliferation and metastasis, we screened for signalling pathways that may be involved in circITGA7 and ITGA7 functions by using RNA-seq and KEGG analysis of SW620 or SW480 cells. As compared with control cells, 563 genes were upregulated and 425 genes were downregulated in the circITGA7 knockdown cells, whereas knockdown of ITGA7 only caused upregulation of 48 genes and downregulation of 77 genes (supplementary material, Figure S7 ). KEGG pathway enrichment analysis indicated that the differentially expressed genes induced by circITGA7 knockdown were mainly enriched for the Ras signalling pathway ( Figure 4A ). In the ITGA7 knockdown cells, the differentially expressed genes were enriched for cytokine-related pathways, such as the cytokine-cytokine receptor interaction, interleukin (IL)-17 and transforming growth factor (TGF)-β signalling pathways ( Figure 4B ).
Given the crucial role of the Ras pathway in CRC tumourigenesis and progression, we investigated whether circITGA7 could modulate the Ras pathway. Western blotting showed that the Ras levels were markedly increased following knockdown of circITGA7 in SW620 and RKO cells. Moreover, phosphorylation of the key downstream effectors of Ras [i.e. extracellular signal-regulated kinase (ERK) and AKT] increased accordingly ( Figure 4C,D) . The opposite effects were observed following the overexpression of circITGA7 ( Figure 4E,F) . These data suggest that circITGA7 is a negative regulator of the Ras signalling pathway.
CircITGA7 binds to miR-370-3p to suppress the Ras signalling pathway by upregulating neurofibromin 1 (NF1)
To further explore the molecular mechanisms involved in the modulation of the Ras signalling pathway by circITGA7, we determined the subcellular location of circITGA7. FISH and RNA subcellular localisation analysis showed that circITGA7 was predominantly localised in the cytoplasm of CRC cells (Figure 5A,B) . Several possible functions of cytoplasmic circRNAs have been proposed, including sponging miRNAs and binding to or encoding proteins [30] . Using the circRNADb database [31] , we predicted that circITGA7 had no protein-coding potential (supplementary material, Figure S8 ).
The ability of circRNAs to act as miRNA sponges has been well validated. Therefore, we speculated that circITGA7 might function by interacting with miRNAs. To validate this hypothesis, miRNAs that may bind to circITGA7 were predicted by the use of five bioinformatics databases (MicroTar, RNAhybrid, miRanda, RegRNA2.0, and CircInteractome) (supplementary material, Supplementary materials and methods). Among the candidate miRNAs, only miR-370-3p was predicted by all five databases (supplementary material, Table S5 ). MiR-370 has been reported to target NF1, a Ras pathway negative regulator, in acute myeloid leukaemia [32] . Thus, we hypothesised that circITGA7 might modulate the Ras pathway through its upregulation of NF1 by competitively binding to miR-370-3p. We used dual-luciferase reporter assays to validate the interaction between circITGA7 or the NF1 3 ′ -UTR and miR-370-3p. First, we generated wild-type and mutational vectors of circITGA7 and NF1 3 ′ -untranslated region (UTR) ( Figure 5C ,D), which were validated by Sanger sequencing (supplementary material, Figure S9 ). The dual-luciferase reporter assays indicated that luciferase activity was decreased in 293 T cells after cotransfection with wild-type (WT) circITGA7-WT or WT NF1 3 ′ -UTR and miR-370-3p mimics ( Figure 5E ). Moreover, western blotting revealed that NF1 levels were decreased in SW620 and RKO cells after transfection with miR-370-3p mimics, but increased following treatment with miR-370-3p inhibitors ( Figure 5F ; supplementary material, Figure S10 ).
To further validate the suppressor effect of circITGA7 on miR-370-3p, miR-370-3p mimics were transfected into SW620 and RKO cells. Western blot analysis showed that the level of NF1 was decreased and that the levels of Ras, phospho-ERK (p-ERK), phospho-AKT (p-AKT) were increased in the transfected cells, and that these effects were attenuated by cotransfection with circITGA7 ( Figure 5G ; supplementary material, Figure S11 ). Similarly, IHC indicated that the level of NF1 was increased and that of Ras was decreased in circITGA7-overexpressing orthotopic tumours ( Figure 5H ; supplementary material, Figure S12 ). Similar results were obtained with western blot analysis ( Figure 5I ). These findings demonstrate that circITGA7 could bind to miR-370-3p to increase NF1 expression, thus suppressing the Ras pathway.
CircITGA7 upregulates its host gene transcription by suppressing RREB1 via the Ras pathway ITGA7 pre-mRNA generates two types of RNA: circIGA7 and linear ITGA7. As they are both downregulated in CRC, we deduced that the level of ITGA7 pre-mRNA is decreased in CRC. Many factors may affect the expression level of ITGA7 pre-mRNA. In the current study, we explored the regulatory role of transcription factors in ITGA7 transcription. Using the CONSITE database [33] , we found seven putative high-scoring recognition sites for RREB1 in the promoter of ITGA7 (supplementary material, Figure S13 ). ChIP analysis validated the direct binding of RREB1 to the ITGA7 promoter ( Figure 6A ). In addition, RT-qPCR revealed that RREB1 was upregulated in CRC tissues as compared with adjacent non-cancerous tissues ( Figure 6B ). Moreover, a negative correlation was observed between RREB1 expression and ITGA7 or circITGA7 expression ( Figure 6C ). However, knockdown of RREB1 increased the linear ITGA7 levels in both SW480 and RKO cells, but did not change the circITGA7 levels ( Figure 6D ), which suggests that there may be splicing competition between back-splicing for circITGA7 biogenesis and canonical splicing for ITGA7 biogenesis.
However, the mechanism of circRNA biogenesis is poorly understood. It has been reported that the reverse complementary sequences, especially Alu sequences, across the flanking introns of circRNA could bring flanking introns close together to promote back-splicing [34] . We found that Alu sequences exist only in the upstream intron of circITGA7, and are absent in the downstream intron ( Figure 6E ). To explore whether the flanking introns and Alu sequences facilitate circITGA7 circularisation, we constructed expression vectors with or without the flanking introns or Alu elements ( Figure 6F ). RT-qPCR results indicated that the presence of the full-length flanking introns led to high circITGA7 expression; no expression was observed when the flanking introns were deleted. However, deletion of only the Alu sequences had little effect on circITGA7 formation ( Figure 6G ). These results suggest that circITGA7 is more probably generated by factors other than the reverse complementary Alu sequences in CRC. Some proteins binding to the flanking introns [35] and exon-containing lariat precursor [36] can also facilitate exon circularisation. Further study is needed to determine which factors regulate circITGA7 circularisation.
In addition, RREB1 can be upregulated and activated by the Ras pathway [37] [38] [39] . Because our data revealed that circITGA7 is a negative regulator of the Ras pathway, we speculated that circITGA7 might increase its host gene transcription by suppressing RREB1 via the Ras pathway. We analysed circITGA7 and ITGA7 expression in the same 46 paired CRC tissues, and found a positive correlation between their expression ( Figure 6H) . As shown by RT-qPCR, ITGA7 levels increased after overexpression of circITGA7 and decreased after circITGA7 knockdown in both SW480 and RKO cells ( Figure 6I) . Furthermore, western blotting showed decreased RREB1 levels and increased ITGA7 levels in circITGA7-overexpressing cells. The opposite effect was observed after knockdown of circITGA7 ( Figure 6J) . Consistent with the western blotting results, IHC revealed decreased RREB1 expression and increased ITGA7 expression in orthotopic tumours derived from circITGA7-overexpressing cells ( Figure 6K ; supplementary material, Figure S12 ). In summary, these data indicate that circITGA7 can upregulate the transcription of its host gene ITGA7 by suppressing RREB1 through inhibition of the Ras pathway.
Discussion
In the current study, we have demonstrated that circITGA7 and ITGA7 are both downregulated in CRC. Gain-of-function and loss-of-function assays revealed that they could both inhibit tumour cell proliferation and metastasis in vitro and in vivo. Mechanistically, circITGA7 suppressed the Ras signalling pathway by competitively binding to miR-370-3p to upregulate NF1 translation. In addition, circITGA7 can upregulate the transcription of its host gene ITGA7 by suppressing RREB1 via the Ras pathway (supplementary material, Figure S14 ).
To date, only a few circRNAs have been reported in CRC [40] . Hsa_circ_0020397 can enhance CRC cell viability and invasion by sponging miR-138 [41] . Similarly, elevated levels of circCCDC66 and circHIPK3 promote CRC growth and metastasis by sponging miRNAs [42, 43] . These studies exemplify circRNAs as oncogenes contributing to CRC progression. However, existing RNA-seq data show that circRNAs are typically downregulated in CRC tissues and CRC cell lines as compared with normal tissues and a normal colon cell line, NCM460 [28, 44, 45] . In addition, some downregulated circRNAs (e.g. hsa_circ_0000567 [46] and hsa_circ_0001649 [47] ) can serve as biomarkers for CRC diagnosis. Furthermore, circITCH can inhibit CRC cell proliferation through the Wnt-β-catenin pathway [48] . However, the function of downregulated circRNAs in CRC is still unexplored. Thus, our study is the first to demonstrate that circITGA7 and its linear host gene ITGA7 are downregulated in CRC and play crucial inhibitory roles in CRC growth and metastasis.
Mechanistically, we found that circITGA7 is a potential negative regulator of the Ras signalling pathway. Ras, the first identified oncogene, is frequently abnormally activated in most cancers, including CRC. Ras activates downstream effector proteins, such as phosphoinositide 3-kinase (PI3K) and RAF1, to modulate the PI3K-AKT and RAF-MEK-ERK pathways [49] , which influence tumourigenesis, growth, invasiveness, angiogenesis, and resistance to anti-epidermal growth factor receptor (EGFR) therapy [50] . Here, we determined that circITGA7 could competitively bind to miR-370-3p to upregulate NF1 expression and modulate the Ras pathway. MiR-370-3p is encoded at 14q32, which has been identified as a cancer-associated genomic region. Previous studies showed that overexpression of miR-370 in lung cancer was associated with poor outcomes [51] , and that miR-370 promotes cancer cell proliferation, invasion and metastasis in melanoma [52] and gastric cancer [53] by targeting PDHB and TGF-β receptor II, respectively. However, miR-370 also functions as a tumour suppressor in ovarian carcinoma [54] . The controversy regarding the functions of miR-370 in malignancies may be due to the different functions of its target genes, which may vary in different cell types or under specific circumstances. Consistent with our data, miR-370 is upregulated in acute myeloid leukaemia and targets NF1 to promote tumour growth [32] . NF1 is a well-known negative regulator of the Ras pathway. Reduced NF1 expression in lung cancer activates the Ras pathway and leads to resistance to anti-EGFR therapy [55] .
In addition, we demonstrated that circITGA7 could promote the transcription of its host gene ITGA7 by suppressing the transcription factor RREB1 via the Ras pathway. We found that the expression of RREB1 was increased in CRC tissues, which is consistent with a previous study [39] . Furthermore, knockdown of RREB1 in CRC cells increased the expression of ITGA7, which indicated that RREB1 was a negative regulator of ITGA7 transcription. RREB1 has been shown to inhibit transcription of the suppressor gene p16 [37] , and overexpression of RREB1 in prostate cancer increased tumour cell survival by reducing transcription of hZIP1 [38] . Although we explored how increased expression of RREB1 could downregulate ITGA7 transcription in CRC, other mechanisms (e.g. genomic mutation, histone modification, DNA methylation, or splicing regulation) may also contribute to the decreased expression of ITGA7 and circITGA7 in CRC, and these require further study.
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